Bruker to acquire majority stake in Hain Lifescience GmbH

Bruker Corporation has signed a definitive agreement to acquire an 80% majority interest in Hain Lifescience GmbH, a German molecular diagnostics company specializing in infectious disease testing. The acquisition is expected to close in Q4 2018. Financial details were not disclosed.

“Bruker expects to acquire an 80% majority interest in Hain, with options for the remaining 20% that can be exercised after 2021.”biospace.com

• 1 source
• biospace.comBruker Announces Agreement to Acquire Majority in Infectious Disease-focused Molecular Diagnostics (MDx) Company Hain Lifescience GmbH - BioSpaceAnnalee ArmstrongAug 24, 2018

Summarized from public sources; check the original articles before acting on it.